View Exam | PowerPak

1. Which of the following is an appropriate use for GLP-1 RAs based on the ADA guidelines?

A. As an add-on to basal insulin B. As an add-on to a basal-bolus insulin regimen C. As first-line monotherapy D. Not recommended, but may still be useful for certain patients

2. CC is a 55-year-old female patient with type 2 diabetes. Her diabetes is currently only being managed with metformin in addition to diet and exercise. Her A1C is still 7.8% and her goal is less than 7%. She has chronic obstructive pulmonary disease, hypertension, and hyperlipidemia. She tried insulin aspart in the past, but it was discontinued because she has several hospitalizations for hypoglycemia. She states that she really doesn't like needles much and would prefer to inject as infrequently as she can. Which of the following injectable medications would be the best choice for CC?

A. Liraglutide B. Pramlintide C. Dulaglutide D. Lixisenatide

3. Which of the following adverse effects is common to all non-insulin injectable medications?

A. Upper respiratory tract infections B. Pancreatitis C. Weight gain D. Nausea

4. How do incretins help regulate blood glucose?

A. Released from the gastrointestinal tract, they slow gastric emptying, promote insulin release, and suppress glucagon release B. Released from the pancreas, they slow gastric emptying and suppress glucagon release C. Released from the gastrointestinal tract, they suppress insulin release and promote glucagon release D. Released from the pancreas, they suppress insulin release and promote glucagon release

5. Which of the following GLP-1 RAs carries an indication for patients with type 2 diabetes and established cardiovascular disease?

Exenatide extended release

B. Liraglutide C. Lixisenatide D. Semaglutide

6. Which of the following is an counseling point for a patient receiving insulin degludec/liraglutide?

A. Your dose of this medication is the same as your current insulin dose. B. You are at lower risk of hypoglycemia with this product than with insulin monotherapy C. If you miss 3 consecutive days of this medication, you should reset your dose to 16 units daily D. This medication must be taken within 1 hour of the first meal of the day.

7. BK is a 45-year-old male patient with type 1 diabetes. His current insulin regimen consists of insulin glargine 10 units every night at bedtime and insulin aspart 15 units with breakfast and lunch and 20 units with dinner. BK's doctor has decided to initiate pramlintide therapy. How should pramlintide be initiated?

A. 15 mcg injected immediately prior to meals; mealtime insulins reduced by 50% B. 15 mcg injected immediately prior to meals; mealtime and basal insulins reduced by 50% C. 60 mcg injected immediately prior to meals; mealtime insulins reduced by 50% D. 60 mcg injected immediately prior to meals; mealtime and basal insulins reduced by 50%

8. Which of the following is true about semaglutide?

A. It is injected once daily without regard to meals B. The most common side effect is hypoglycemia C. The maximum dose is 1.8 mg injected once weekly D. It remains in circulation for about 5 weeks after the last dose

9. Which of the following would be an appropriate counseling point for a patient using the extended release exenatide single dose kit?

A. This medication must be injected within 30 to 60 minutes prior to a meal B. If you miss a dose of this medication you must administer it the same day or wait until the next scheduled dose C. This medication may cause your appetite to increase so it may be helpful to administer with meals D. This medication must be prepared for administration by mixing the contents of the vial with the liquid in the syringe